Status:
COMPLETED
High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
Lead Sponsor:
Stanford University
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
To assess the role of autologous hematopoietic cell rescue in the treatment of multiple myeloma.
Detailed Description
To assess the toxicity and efficacy of sequentially administered high dose cyclophosphamide and VP-16 followed by total body irradiation or BCNU and high dose mephalan and autologous stem cell rescue ...
Eligibility Criteria
Inclusion
- received cytoreduction prior to transplant
- adequate organ function
Exclusion
- previous transplant
- smoldering MM or benign monoclonal gammopathy
Key Trial Info
Start Date :
September 1 1994
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2010
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00186238
Start Date
September 1 1994
End Date
April 1 2010
Last Update
September 14 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305